Jaguar Health licensed U.S. commercial rights for Mytesi and Canalevia-CA1 to Future Pak for $16 million upfront plus $2 million contingent payment, driving Q1 2026 net revenue to approximately $19.3 million. The company is refocusing on crofelemer development for rare-disease intestinal failure indications while exiting U.S. prescription product sales operations.